Congress Day One
Tuesday, September 7, 2021
All time in CET (EET = +1hr / BST = -1hr / EST = -6hr)
09:00 LSX Welcome
Josh Dance, SVP, LSX
09:10 Keynote Presentation: How Nasdaq Nordics Markets are Driving Growth Capital for Nordic Life Sciences
Adam Kostyal, SVP, Nasdaq
10:00 Keynote Panel: Nordic Life Sciences, Further Globally Recognised – What’s Next for the Thriving Ecosystem?
Whilst a challenging year for many reasons, 2020 felt like a step change in Nordics putting an already attractive even more firmly on the map. A number of companies passed significant private and public fundraising, clinical and company development milestones, and these positives stories continued through into 2021.
While the life sciences and healthcare industry was put ever-more under focus, in the Nordics particularly the increased capital flow and interest from international investors, pharma and other key stakeholders interested in playing their part to continue to build the maturing Nordic ecosystem was clear to see. What is next for the sector as a whole and how are these companies planning to grow, develop and internationalise further?
Martin Welschof, CEO, BioInvent
Mai-Britt Zocca, CEO, IO Biotech
Anders Martin-Löf, CFO, Oncopeptides
Renee Aguiar-Lucander, CEO, Calliditas Therapeutics
11:00 Presentation & Panel: Success in Investment in the Nordics and Europe – Time to Recalibrate?
While challenges, opportunities and focus areas for investment are often discussed at length, what does analysis of key wider industry trends tell us about the true dynamics of European life sciences investment, and how it’s changing? Leading Nordic and European investors discuss what learnings can investors and companies alike take from key investment metrics.
Søren Lemonius, Managing General Partner, Sunstone Life Science Ventures
Søren Moller, Managing Partner, Novo Seeds
Ann-Tove Kongsnes, Investment Director, Investinor
Moderator: Tony Proctor, Partner, Potter Clarkson
12:00 Fireside Chat: Evolving VC Strategies - Pipes and Venture in Public Equities
With strong institutional investors and a strong retail investor market, the route public for companies in the Nordics often happens earlier, which can lead to financing challenges and bottlenecks further down the line. Life science specialist VC firms in the Nordics and across Europe are increasingly breaking the mould and investing in public companies alongside private investments. Why and when would VCs allocate funds to public companies?
Ingrid Teigland Akay, Managing Partner, Hadean Ventures
14:00 Panel: Leading European Healthtech Innovation – Investment, Expansion and Internationalisation
While the wider European healthtech market is booming, the Nordics has become a frontrunner in digital innovation in healthcare. Nordic digital health and healthech innovation is gaining massive traction and attracting major investment. What has been key to this success and what is needed to secure the region as a globally competitive digital health innovation hub?
Mats Berggren, Head of Digital Growth Opportunities and Innovation, Merck Group
Anna-Karin Edstedt Bonamy, CEO, Doctrin
15:00 Presentation: Global Registrations – Synergies Between US and Europe Medical Device Registration
Jan Bart Hak, Head of Medical Device Department, ProPharma Group
16:00 Panel: Preparing for and Executing Successful Cross-Border Transactions
Life sciences is a global industry and cross-border deals are often critical for growth and internationalisation plans. Scientific, market, structural and cultural challenges are all key considerations in successful licencing, partnering or M&A deal across borders. Executives explore the optimal means of preparation of materials, readiness with relevant data and planning, as well as the pitfalls in these critical endeavours.
Søren Bregenholt, CEO, Alligator Bioscience
Magnus Corfitzen, CEO, Ascelia Pharma
Gunilla Oswald, CEO, BioArctic
Nathalie ter Wengel, European Lead Worldwide Business Development, Pfizer
Moderator: Greg Benning, Managing Director, Back Bay Life Science Advisors
17:00 Video Networking Reception